{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:35:53Z","timestamp":1794062153407,"version":"4.8.0"},"reference-count":16,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.25-0514","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:09:00Z","timestamp":1765404540000},"page":"n\/a","source":"Crossref","is-referenced-by-count":4,"title":["A Case of Grade 4 Hyperglycemia Induced by Capivasertib and Successfully Managed with Early Insulin Intervention"],"prefix":"10.70352","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1065-7124","authenticated-orcid":false,"given":"Yuki","family":"Nomoto","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Kagoshima City Hospital, Kagoshima, Kagoshima, Japan"},{"name":"Department of Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, Kagoshima City Hospital, Kagoshima, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Kagoshima City Hospital, Kagoshima, Kagoshima, Japan"},{"name":"Department of Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiji","family":"Yoshinaka","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Kagoshima City Hospital, Kagoshima, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Shinden","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nakajo","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 2023; 388: 2058\u201370.","DOI":"10.1056\/NEJMoa2214131"},{"key":"2","unstructured":"2) Japan Diabetes Society. Safety warning on hyperglycemia and DKA associated with AKT inhibitor capivasertib. 2025. (in Japanese). https:\/\/www.jds.or.jp\/uploads\/files\/document\/info\/jds_capivasertib_info_2025-04-15.pdf.  Accessed 17 Jul 2025."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Nunnery SE, Mayer IA. Targeting the PI3K\/AKT\/mTOR pathway in hormone positive breast cancer. Drugs 2020; 80: 1685\u201397.","DOI":"10.1007\/s40265-020-01394-w"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Su R, Shao Y, Huang M, et al. Immunometabolism in cancer: basic mechanisms and new targeting strategy. Cell Death Discov 2024; 10: 236.","DOI":"10.1038\/s41420-024-02006-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Rowland AF, Fazakerley DJ, James DE. Mapping insulin\/GLUT4 circuitry. Traffic 2011; 12: 672\u201381.","DOI":"10.1111\/j.1600-0854.2011.01178.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Gillespie KM. Type 1 diabetes: pathogenesis and prevention. CMAJ 2006; 175: 165\u201370.","DOI":"10.1503\/cmaj.060244"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Javeed N, Matveyenko AV. Circadian etiology of type 2 diabetes mellitus. Physiology (Bethesda) 2018; 33: 138\u201350.","DOI":"10.1152\/physiol.00003.2018"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Rugo HS, Oliveira M, Howell SJ, et al. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open 2024; 9: 103697.","DOI":"10.1016\/j.esmoop.2024.103697"},{"key":"9","unstructured":"9) Astra Zeneca KK. Early post-marketing surveillance report on Truqap<sup>\u00ae<\/sup> (capivasertib). 2025. (in Japanese). https:\/\/www.sotsugo.com\/img\/file73.pdf. Accessed 17 Jul 2025."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Dent RA, Kim SB, Oliveira M, et al. Ipatasertib plus paclitaxel for patients with <i>PIK3CA\/AKT1\/PTEN<\/i>-altered locally advanced unresectable or metastatic triple-negative breast cancer in the IPATunity130 phase 3 trial. Clin Cancer Res 2024; 30: 4329\u201338.","DOI":"10.1158\/1078-0432.CCR-24-0465"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Turner N, Dent RA, O\u2019Shaughnessy J, et al. Ipatasertib plus paclitaxel for <i>PIK3CA\/AKT1\/PTEN<\/i>-altered hormone receptor-positive, HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat 2022; 191: 565\u201376.","DOI":"10.1007\/s10549-021-06450-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Rugo HS, Andr\u00e9 F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 2020; 31: 1001\u201310.","DOI":"10.1016\/j.annonc.2020.05.001"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer. N Engl J Med 2012; 366: 520\u20139.","DOI":"10.1056\/NEJMoa1109653"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Rodriguez YE, Batra R, Patel K, et al. Capivasertib-induced diabetic ketoacidosis in a patient with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative (ER+\/HER2-) metastatic breast cancer and no prior history of diabetes mellitus: a case report. Cureus 2024; 16: e63710.","DOI":"10.7759\/cureus.63710"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Habeb B, Valdes O, Khair S, et al. Capivasertib-induced diabetic ketoacidosis in a non-diabetic patient with metastatic prostate cancer with bone involvement: a case report of a rare but serious metabolic complication. Cureus 2025; 17: e81513.","DOI":"10.7759\/cureus.81513"},{"key":"16","unstructured":"16) Japan Diabetes Society. Clinical practice guidelines for diabetes. 2024. (in Japanese). https:\/\/www.jds.or.jp\/uploads\/files\/publications\/gl2024\/20.pdf. Accessed 17 Jul 2025."}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0514\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:42:52Z","timestamp":1765600972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0514\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0514","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.25-0514"}}